Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | DBH | P09172 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93982 | 0.79 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL3298586 | 0.78 | IDO1 (0.64) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL407334 | 0.76 | IDO1 (0.61) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL17372921 | 0.76 | IDO1 (0.61) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL29494831 | 0.76 | IDO1 (0.61) | IDO1PNMTTAAR1SIGMAR1POLB | |
| Bromide SCHEMBL1964769 | 0.74 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL92905 | 0.74 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL9663794 | 0.74 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL17552687 | 0.74 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL9788481 | 0.74 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1023044-B1 | APATITE-COATED SOLID COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20030185878-A1 | Process for producing phospholipid-containing drug | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6552054-B1 | For prophylaxis and therapy of bone diseases and chondropathy | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-1293197-A1 | PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6531604-B2 | Useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-11 | — | — | US | disclosed |
| EP-0949927-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OSTEOGENESIS-PROMOTING SUBSTANCE AND A POLYETHYLENE GLYCOL | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-16 | — | — | EP | disclosed |
| US-5376647-A | A pyridyl-sulfur contained-alkylaminomethylene bisphosphonic acid derivatives treating osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0376197-B1 | Sulfur-containing heterocyclic compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5280022-A | Containing an amine group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| US-5158943-A | Osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0491374-A1 | Bisphosphonic acid derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-24 | — | — | EP | disclosed |
| EP-0464509-A1 | Biphosphonic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0460488-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-5071841-A | For prevention of bone reabsorption | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0376197-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0155486-A1 | 1,3,5-Trisubstituted 1,2,4-triazole derivatives, process for their preparation and medicinal preparations containing them | ALKALOIDA VEGYéSZETI GYáR (HU) | 1985-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | PHOSPHO1, PLTP, PTDSS2 | IDO1 1709/4885PNMT 694/4885TAAR1 1397/4885 |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | IDO1 1533/4885PNMT 330/4885TAAR1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.